Taro Pharma (TARO) Reports Q3 EPS of $4.41

Taro Pharma (NYSE: TARO) reported Q3 EPS of $4.41, versus $3.33 reported last year. Revenue for the quarter came in at $258.3 million, versus $237.7 million reported last year.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79